ACADIA Pharmaceuticals Inc Company News
SAN DIEGO, April 29, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it has awarded 10 academic scholarships to eligible recipients of the first Rett Sibling Scholarship. The Rett Sibling Scholarship program, sponsored by Acadia, was established in 2023 to recognize the siblings of individuals with Rett syndrome. This year’s recipients will each receive $5,000 to pursue their goals in higher education for the 2024-25 academic school year.
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market...
SAN DIEGO, April 24, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report first quarter financial results on Wednesday, May 8, 2024, after the close of the U.S. financial markets. Acadia’s management team will also host a conference call and webcast on May 8, 2024, at 4:30 p.m. Eastern Time to discuss financial results and operations.
SAN DIEGO, April 22, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has accepted its New Drug Submission (NDS) for trofinetide for the treatment of Rett syndrome, a rare neurodevelopmental disorder. Health Canada has granted Priority Review for Acadia’s submission.
SAN DIEGO, April 19, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that on April 10, 2024, the Compensation Committee of Acadia’s Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 21,659 shares of common stock and 12,739 restricted stock units ("RSUs") to six new employees under Acadia’s 2023 Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employme
SAN DIEGO, April 17, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that two oral presentations featuring DAYBUE™ (trofinetide) findings in Rett syndrome will be presented at the American Academy of Neurology (AAN) 2024 annual meeting, being held this week in Denver, CO.
There are some pharma stocks to sell in April. Holding these companies is too risky, especially as the industry faces increasing regulatory scrutiny and pricing pressures. Several major pharmaceutical firms are grappling with patent cliffs, where key drug exclusivities are expiring. This opens the door for generic competition. Moreover, with the broader market presenting attractive investment options, holding on to these riskier pharma plays could result in significant opportunity cost. Many pro
ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders, has reported an insider sell transaction.
SAN DIEGO, April 02, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr. Elizabeth H. Z. Thompson as Executive Vice President, Head of Research and Development. Dr. Thompson will lead research and development at Acadia and serve as a member of the company’s Executive Leadership Team, reporting to Steve Davis, Chief Executive Officer of Acadia.
SAN DIEGO, April 01, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024 at 3:45 p.m. Eastern Time.
Stephen Davis, the CEO of ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), has sold 17,714 shares of the company on March 27, 2024, according to a recent SEC filing.
Recent trends in the stock market have seen a shift in investor interest from tech giants, known as the Magnificent 7, towards pharmaceutical companies, particularly those involved in weight-loss drugs. But, it’s important to identify which pharma stocks to sell before they plummet, as not all will benefit equally from the hype. As a result, pharmaceutical companies like Eli Lilly (NYSE:LLY), Pfizer (NYSE:PFE) and Novo Nordisk (NYSE:NVO) are attracting retail investors’ attention given their por
SAN DIEGO, March 13, 2024--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in the UBS Virtual CNS Day on Monday, March 18, 2024 at 2:00 p.m. Eastern Time.
Acadia stock crashed Tuesday after an outsized placebo effect torpedoed the company's efforts to expand Nuplazid to schizophrenia patients.
Old Arcived News About ACADIA Pharmaceuticals Inc
- 9:01 am ACADIA Pharmaceuticals announces that it has appointed Julian Baker, of Baker Brothers Investments to its Board of Directors.
- ACADIA Pharmaceuticals (ACAD) Is Today's Dead Cat Bounce Stock.
- ACADIA Pharmaceuticals Appoints Edmund P. Harrigan, M.D., to Board of Directors. [at noodls] - SAN DIEGO--(BUSINESS WIRE)--Nov. 30, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet ...
- ACADIA Pharmaceuticals Appoints Julian C. Baker to Board of Directors. [at noodls] - --(BUSINESS WIRE)--Dec. 15, 2015-- (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous ...
- ACADIA Pharmaceuticals Appoints Srdjan. [at noodls] - SAN DIEGO--(BUSINESS WIRE)--Nov. 30, 2015-- ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet ...
- ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers.
- ACADIA PHARMACEUTICALS INC Financials.
- ACADIA Pharmaceuticals Inc..
- ACADIA Pharmaceuticals Presents Caregiver Burden Data at the International Congress of Non-Motor Dysfunctions in Parkinson’s Disease and Related Disorders. [at noodls] - ACADIA Pharmaceuticals Presents Caregiver Burden Data at the International Congress of Non-Motor Dysfunctions in Parkinson's Disease and Related Disorders Data Demonstrate a Decreased Burden Among Caregivers ...
- ACADIA Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : December 4, 2015.
- ACADIA Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : November 10, 2015.
- Acadia reports 3Q loss.
- Analysts' Actions -- Alaska Air, Avon, Bristol-Myers, Goldman Sachs and More.
- Myriad Genetics: Top Performer in the Biotechnology Subgroup.
- Strong On High Volume: ACADIA Pharmaceuticals (ACAD).
- Today's Dead Cat Bounce Stock Is ACADIA Pharmaceuticals (ACAD).
- Today's Dead Cat Bounce Stock: ACADIA Pharmaceuticals (ACAD).
- Top 5 Healthcare Bets of World-Class Baker Bros. Advisors.
- Trade-Ideas: ACADIA Pharmaceuticals (ACAD) Is Today's Weak On High Relative Volume Stock.
- We Dig Into the Smart Money Sentiment Towards Nice Systems Ltd.
ACADIA Pharmaceuticals Inc Short Company Overview:
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company is currently working on the treatment of induced dysfunction in Parkinson's disease ,schizophrenia, neuropathic pain and glaucoma.
